Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
RSS SUMMARY · AGGREGATED FROM CNBC
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
Continue Reading
The full story continues on CNBC.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
CNBC
Business
Inflation hits 3.2% in the euro zone as Iran war pushes energy costs higher
CNBC·1h ago·3 min read
US
Amazon’s four-day Prime Day event starts June 23, as shoppers battle inflation
CNBC·5h ago·3 min read
US
Trump administration proposes 25% tariff on Brazilian goods over unfair trade practices
CNBC·6h ago·3 min read
US
Blue Origin launchpad damaged in rocket explosion may not be restored until 2028, NASA’s Isaacman says
CNBC·11h ago·3 min read
Related
On this beat
Health
Health Care Roundup: Market Talk
TWSJ·22m ago·3 min read
Health
Abivax Shares Plunge After Company Reports Adverse Events in Key Drug Trial
TWSJ·2h ago·3 min read
Health
She got a $911,400 bill for treatment that was supposed to be free. The autism-therapy industry is booming—and so are the billing abuses.
TWSJ·10h ago·3 min read
Health
As Ebola Spreads, Scientists Race to Find Vaccines and Treatments
TNYT·10h ago·3 min read